Skip to content
value.today
Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2015
Total raised
$300 M
2 rounds on record
Latest round
$230 M
Jul 2018
First round on record
Jan 2018
Today
Went public
See the company page

Gossamer Bio, Inc. is listed today as Gossamer Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Gossamer Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$25 MPrivate placement after listing$10 to $50 million

Gossamer Bio, Inc.: Private sale, Aug 2026

Investors in this round

38 investors had bought by the notice of Sep 4, 2026: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Gossamer Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $150 M offered; $125 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,375,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan D. Giraudo · Executive Officer
  • Caryn D. Peterson · Executive Officer
  • Christian D. Waage · Executive Officer
  • Faheem Hasnain · Executive Officer, Director
  • Robert D. Smith · Executive Officer
  • John D. Quisel · Director
  • Russell Cox · Director
  • Sandra J. Milligan · Director
  • Skye J. Drynan · Director
  • Steven D. Nathan · Director
  • Thomas Daniel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states, and outside the US
  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in all US states

Signed by Bryan Giraudo, Coo & cfo. Source: SEC Form D, newest notice filed Sep 4, 2026. Read the notice at the SEC.

optionsSEC
Jul 2023$212 MPrivate placement after listing$50 to $250 million

Gossamer Bio, Inc.: Private sale, Jul 2023

Investors in this round

70 investors had bought by the notice of Aug 7, 2023: 70 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Gossamer Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$212 M of $212 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$10,482,807
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Giraudo · Executive Officer
  • Caryn Peterson · Executive Officer
  • Christian Waage · Executive Officer
  • Faheem Hasnain · Executive Officer, Director
  • Richard Aranda, M.D. · Executive Officer
  • Kristina Burow · Director
  • Renee Gala · Director
  • Russell Cox · Director
  • Sandra Milligan, M.D., J.D. · Director
  • Thomas Daniel, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Wedbush Securities Inc. (CRD 877) · Los Angeles, CaliforniaSold in all US states
  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states
  • Piper Sandler & Co. (CRD 665) · Minneapolis, MinnesotaSold in all US states
  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Signed by Bryan Giraudo, Chief Operating Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 7, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2022$120 MPrivate placement after listing$50 to $250 million

Gossamer Bio, Inc.: Private sale, Jul 2022

Investors in this round

23 investors had bought by the notice of Jul 18, 2022: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Gossamer Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$120 M of $120 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Giraudo · Executive Officer
  • Caryn Peterson · Executive Officer
  • Christian Waage · Executive Officer
  • Faheem Hasnain · Executive Officer, Director
  • Laura Carter, Ph.D. · Executive Officer
  • Richard Aranda, M.D. · Executive Officer
  • Joshua Bilenker, M.D. · Director
  • Kristina Burow · Director
  • Renee Gala · Director
  • Russell Cox · Director
  • Sandra Milligan, M.D., J.D. · Director
  • Thomas Daniel, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Faheem Hasnain, President, CEO, and Chairman of the Board of Directors. Source: SEC Form D, newest notice filed Jul 18, 2022. Read the notice at the SEC.

equitySEC
Jul 2018$230 MNo. 2$50 to $250 million

Gossamer Bio, Inc.: Raise no. 2, Jul 2018

Investors in this round

67 investors had bought by the notice of Aug 1, 2018: 67 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Gossamer Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$230 M of $230 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Giraudo · Executive Officer
  • Christian Waage · Executive Officer
  • Jill Howe · Executive Officer
  • Sheila Gujrathi, M.D. · Executive Officer, Director
  • Faheem Hasnain · Director
  • Kristina Burow · Director
  • Michael Yi · Director
  • Otello Stampacchia, Ph.D. · Director
  • Richard Lim · Director
  • Robert Nelsen · Director
  • Thomas Daniel, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christian Waage, Secretary. Source: SEC Form D, newest notice filed Aug 1, 2018. Read the notice at the SEC.

equitySEC
Jan 2018$70 MNo. 1$50 to $250 million

Gossamer Bio, Inc.: Raise no. 1, Jan 2018

Investors in this round

3 investors had bought by the notice of Jan 19, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Gossamer Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$70 M of $80 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christian Waage · Executive Officer
  • Faheem Hasnain · Executive Officer, Director
  • Sheila Gujrathi, M.D. · Executive Officer, Director
  • Kristina Burow · Director
  • Otello Stampacchia, Ph.D. · Director
  • Richard Lim · Director
  • Robert Nelsen · Director
  • Thomas Daniel, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christian Waage, Treasurer and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Jan 19, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Gossamer Bio, Inc., its revenue in fiscal 2025 came from these product and service lines: Revenue from contracts with collaborators $48.47 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Gossamer Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2026

Products and services#

No products or services of Gossamer Bio, Inc. are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Gossamer Bio, Inc.
InvestorKindAmountRoundRoleSource
ARCH Venture Fund IX, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Fund IX Overage, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Partners IX, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Partners IX Overage, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Bryan GiraudoPersonnot statednot statedHeld Series A and B preferred stock (Form 3, 2019)SEC Form 3
Omega Fund V GP, L.P.Fund or asset managernot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Omega Fund V GP Manager, Ltd.Fund or asset managernot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Omega Fund V, L.P.Fund or asset managernot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 67 investors.

Largest shareholders today

Institutions holding Gossamer Bio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Gossamer Bio, Inc.
NameRoleNamed in
Bryan D. GiraudoExecutive officerSep 2026
Caryn D. PetersonExecutive officerSep 2026
Christian D. WaageExecutive officerSep 2026
Faheem HasnainExecutive officerSep 2026
Robert D. SmithExecutive officerSep 2026
Bryan GiraudoExecutive officerAug 2023
Caryn PetersonExecutive officerAug 2023
Christian WaageExecutive officerAug 2023
Richard Aranda, M.D.Executive officerAug 2023
Laura Carter, Ph.D.Executive officerJul 2022
Jill HoweExecutive officerAug 2018
Sheila Gujrathi, M.D.Executive officerAug 2018
Faheem HasnainDirectorSep 2026
John D. QuiselDirectorSep 2026
Russell CoxDirectorSep 2026
Sandra J. MilliganDirectorSep 2026
Skye J. DrynanDirectorSep 2026
Steven D. NathanDirectorSep 2026
Thomas DanielDirectorSep 2026
Kristina BurowDirectorAug 2023
Renee GalaDirectorAug 2023
Sandra Milligan, M.D., J.D.DirectorAug 2023
Thomas Daniel, M.D.DirectorAug 2023
Joshua Bilenker, M.D.DirectorJul 2022
Michael YiDirectorAug 2018
Otello Stampacchia, Ph.D.DirectorAug 2018
Richard LimDirectorAug 2018
Robert NelsenDirectorAug 2018
Sheila Gujrathi, M.D.DirectorAug 2018

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.